Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
2.060
+0.030 (1.48%)
At close: Apr 28, 2026, 4:00 PM EDT
2.060
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Acurx Pharmaceuticals Stock Forecast
ACXP's stock price has decreased by -75.16% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Acurx Pharmaceuticals stock have an average target of 95.5, with a low estimate of 31 and a high estimate of 160. The average target predicts an increase of 4,535.92% from the current stock price of 2.06.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 30, 2025.
Analyst Ratings
The average analyst rating for Acurx Pharmaceuticals stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $31 | Strong Buy | Reiterates | $31 | +1,404.85% | Sep 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $31 | Strong Buy | Maintains | $8 → $31 | +1,404.85% | Aug 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $160 | Strong Buy | Initiates | $160 | +7,666.99% | May 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $240 | Strong Buy | Reiterates | $240 | +11,550.49% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $240 | Strong Buy | Reiterates | $240 | +11,550.49% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.20
from -5.32
EPS Next Year
-2.13
from -2.20
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.77 | -1.94 | |
| Avg | -2.20 | -2.13 | |
| Low | -2.63 | -2.50 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.